Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
MNOV's Cash to Debt is ranked higher than
100% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. MNOV: No Debt )
MNOV' s 10-Year Cash to Debt Range
Min: 0.67   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: -4.10
M-Score: -6.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -153.72
MNOV's Operating margin (%) is ranked higher than
67% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. MNOV: -153.72 )
MNOV' s 10-Year Operating margin (%) Range
Min: -15787.12   Max: -66.98
Current: -153.72

-15787.12
-66.98
Net-margin (%) -153.25
MNOV's Net-margin (%) is ranked higher than
67% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. MNOV: -153.25 )
MNOV' s 10-Year Net-margin (%) Range
Min: -13518.94   Max: -67.12
Current: -153.25

-13518.94
-67.12
ROE (%) -37.72
MNOV's ROE (%) is ranked higher than
70% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. MNOV: -37.72 )
MNOV' s 10-Year ROE (%) Range
Min: -788.84   Max: -19.99
Current: -37.72

-788.84
-19.99
ROA (%) -31.62
MNOV's ROA (%) is ranked higher than
69% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. MNOV: -31.62 )
MNOV' s 10-Year ROA (%) Range
Min: -172.07   Max: -16.41
Current: -31.62

-172.07
-16.41
ROC (Joel Greenblatt) (%) -582.04
MNOV's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. MNOV: -582.04 )
MNOV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39131.25   Max: -108.93
Current: -582.04

-39131.25
-108.93
EBITDA Growth (3Y)(%) -29.60
MNOV's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. MNOV: -29.60 )
MNOV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -83.3   Max: 188.9
Current: -29.6

-83.3
188.9
EPS Growth (3Y)(%) -31.80
MNOV's EPS Growth (3Y)(%) is ranked higher than
60% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MNOV: -31.80 )
MNOV' s 10-Year EPS Growth (3Y)(%) Range
Min: -86.2   Max: 254
Current: -31.8

-86.2
254
» MNOV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MNOV Guru Trades in

MNOV Guru Trades in

Q3 2014

MNOV Guru Trades in Q3 2014

Jim Simons 49,400 sh (New)
» More
Q4 2014

MNOV Guru Trades in Q4 2014

Jim Simons 115,800 sh (+134.41%)
» More
» Details

Insider Trades

Latest Guru Trades with MNOV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.60
MNOV's P/B is ranked higher than
75% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. MNOV: 4.60 )
MNOV' s 10-Year P/B Range
Min: 0.18   Max: 4.68
Current: 4.6

0.18
4.68
PFCF 20.40
MNOV's PFCF is ranked higher than
98% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MNOV: 20.40 )
MNOV' s 10-Year PFCF Range
Min: 20.4   Max: 222.5
Current: 20.4

20.4
222.5
POCF 148.33
MNOV's POCF is ranked higher than
90% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MNOV: 148.33 )
MNOV' s 10-Year POCF Range
Min: 0   Max: 0
Current: 148.33

EV-to-EBIT -10.82
MNOV's EV-to-EBIT is ranked higher than
81% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MNOV: -10.82 )
MNOV' s 10-Year EV-to-EBIT Range
Min: -28   Max: 1.6
Current: -10.82

-28
1.6
Current Ratio 7.61
MNOV's Current Ratio is ranked higher than
83% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. MNOV: 7.61 )
MNOV' s 10-Year Current Ratio Range
Min: 1.59   Max: 31.27
Current: 7.61

1.59
31.27
Quick Ratio 7.61
MNOV's Quick Ratio is ranked higher than
84% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. MNOV: 7.61 )
MNOV' s 10-Year Quick Ratio Range
Min: 1.59   Max: 31.27
Current: 7.61

1.59
31.27

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.70
MNOV's Price/Net Cash is ranked higher than
68% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 109.90 vs. MNOV: 15.70 )
MNOV' s 10-Year Price/Net Cash Range
Min: 0.87   Max: 19.45
Current: 15.7

0.87
19.45
Price/Net Current Asset Value 15.70
MNOV's Price/Net Current Asset Value is ranked higher than
66% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 45.70 vs. MNOV: 15.70 )
MNOV' s 10-Year Price/Net Current Asset Value Range
Min: 0.83   Max: 10.86
Current: 15.7

0.83
10.86
Price/Tangible Book 13.20
MNOV's Price/Tangible Book is ranked higher than
50% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. MNOV: 13.20 )
MNOV' s 10-Year Price/Tangible Book Range
Min: 0.4   Max: 54.67
Current: 13.2

0.4
54.67
Earnings Yield (Greenblatt) -10.10
MNOV's Earnings Yield (Greenblatt) is ranked higher than
57% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. MNOV: -10.10 )
MNOV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.1   Max: 8448.3
Current: -10.1

-10.1
8448.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
Traded in other countries:4875.Japan, RMN.Germany,
MediciNova Inc was incorporated in the State of Delaware on September 2000.It is a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the U.S. market. The Company operates in a single industry segment - the discovery and development of small molecule therapeutics. Its core programs includes, MN-001 (NASH), MN-166 (Neurology Diseases) and MN-221 (Respiratory Diseases). Its non-core programs include, MN-001 (Bronchial Asthma), MN-001 (Interstitial Cystitis), MN-029 (Cancer) and MN-221 (Preterm Labor). The Company is subject to government regulations, in the U.S., the FDA, under the Federal Food, Drug and Cosmetic Act, as amended, and other federal statutes and regulations.
» More Articles for NAS:MNOV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation Apr 16 2015
Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan Apr 16 2015
Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan Apr 16 2015
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH... Apr 16 2015
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH... Apr 16 2015
MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Apr 03 2015
MEDICINOVA INC Financials Mar 19 2015
MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting... Mar 14 2015
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure Mar 13 2015
MEDICINOVA INC Files SEC form 10-K, Annual Report Mar 12 2015
MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting... Mar 02 2015
MediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at... Feb 25 2015
MediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at... Feb 25 2015
MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS Feb 16 2015
MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS Feb 16 2015
MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF Feb 10 2015
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment... Feb 03 2015
MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology... Feb 02 2015
MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at the American Academy of... Feb 01 2015
MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at the American Academy of... Feb 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK